Hematopoietic Stem Cell Transplantation in Children with Inborn Errors of Immunity: a Multi-center Experience in Colombia



To characterize the pediatric population with inborn errors of immunity (IEI) that was treated with hematopoietic stem cell transplantation (HSCT) in three reference centers in Colombia. What have been the characteristics and outcomes of hematopoietic stem cell transplantation in pediatric patients with inborn errors of immunity in three reference care centers in Colombia between 2007 and 2018?


We conducted an observational, retrospective cohort study in children with a diagnosis of IEI who underwent HSCT between 2007 and 2018.


Forty-seven patients were identified, and 5 were re-transplanted. Sixty-eight percent were male. The median age at diagnosis was 0.6 years, and for HSCT was 1.4 years. The most common diseases were chronic granulomatous disease (38%) followed by severe combined immune deficiencies (19%) and hemophagocytic lymphohistiocytosis (15%). Cord blood donors were the most used source of HSCT (44%). T cell–replete grafts from haploidentical donors using post-transplantation cyclophosphamide represent 37% of the cohort. All patients received conditioning, 62% with a non-myeloablative regimen. Calcineurin inhibitors were the main graft-versus-host disease prophylaxis (63.8%). Acute graft-versus-host disease developed in 35% of the total patients. The most frequent post-transplant infections were viral and fungal infections. The 1-year overall survival rates for the patients who received HSCT from identical, haploidentical, and cord sources were 80%, 72%, and 63%, respectively. The 5-year overall survival was 63%.


HSCT is a curative treatment option for some IEI and can be performed with any donor type. Early and timely treatment in referral centers can improve survival.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Fundación Valle del Lili (Cali), Hospital Pablo Tobón Uribe (Medellín) and HOMI Fundación Hospital Pediátrico la Misericordia (Bogotá).


  1. 1.

    Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.

    Article  Google Scholar 

  2. 2.

    Hoyos-Bachiloglu R, Cristian Sotomayor F, Cecilia PH. Severe combined immunodeficiency: the time for newborn screening has come. Rev Chil Pediatr. 2019;90(6):581–8.

    PubMed  Google Scholar 

  3. 3.

    Bakhtiar S, Fekadu J, Seidel MG, Gambinieri E. Allogeneic hematopoietic stem cell transplantation for congenital immune dysregulatory disorders. Front Pediatr. 2019;7(November):1–10.

    Google Scholar 

  4. 4.

    Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2(7583):1366–9.

    CAS  Article  Google Scholar 

  5. 5.

    Gennery AR, Albert MH, Slatter MA, Lankester A. Hematopoietic stem cell transplantation for primary immunodeficiencies. Front Pediatr. 2019;7(October):7–10.

  6. 6.

    Slatter MA, Gennery AR. Hematopoietic cell transplantation in primary immunodeficiency–conventional and emerging indications. Expert Rev Clin Immunol [Internet]. 2018;14(2):103–14. Available from: 10.1080/1744666X.2018.1424627.

  7. 7.

    Fernandes JF, Nichele S, Daudt LE, Tavares RB, Seber A, Kerbauy FR, et al. Transplantation of hematopoietic stem cells for primary Immunodeficiencies in Brazil: challenges in treating rare diseases in developing countries. J Clin Immunol. 2018;38(8):917–26.

  8. 8.

    Montoya CJ, Henao J, Salgado H, Olivares MM, López JA, Rugeles C, et al. Diagnóstico fenotípico de las inmunodeficiencias primarias en Antioquia, Colombia, 1994-2002. Biomédica. 2002;22(4):510.

  9. 9.

    Rocha YC, López JÁ, Orrego JC, Coll Y, Karduss A, Rosenzweig S, et al. Reconstitución inmune exitosa mediante trasplante de células madre hematopoyéticas en un paciente colombiano afectado con enfermedad granulomatosa crónica. Biomedica. 2016;36(2):204–12.

  10. 10.

    Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant [Internet] 2009;15(12):1628–33. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879109003231

  11. 11.

    Lum SH, Hoenig M, Gennery AR, Slatter MA. Conditioning regimens for hematopoietic cell transplantation in primary immunodeficiency. Curr Allergy Asthma Rep. 2019;19(11).

  12. 12.

    Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant [Internet]. 2015;21(4):604–11. Available from:. https://doi.org/10.1016/j.bbmt.2014.08.014.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Onoda M, et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol. 2006;81(11):838–44.

  14. 14.

    Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855–64.

    CAS  Article  Google Scholar 

  15. 15.

    Carreras E, Dufour C, Monty M, Kroger N. The EBMT Handbook [Internet]. Carreras E, Dufour C, Mohty M, Kröger N, editors. Cham: Springer International Publishing; 2019. 320–326 p. Available from: http://link.springer.com/10.1007/978-3-030-02278-5

  16. 16.

    Hahn T, Sucheston-Campbell LE, Preus L, Zhu X, Hansen JA, Martin PJ, et al. Establishment of definitions and review process for consistent adjudication of cause-specific mortality after allogeneic unrelated-donor hematopoietic cell transplantation. Biol Blood Marrow Transplant [Internet]. 2015;21(9):1679–86 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879115003766.

  17. 17.

    Norman M, David C, Wainstein B, Ziegler JB, Cohn R, Mitchell R, et al. Haematopoietic stem cell transplantation for primary immunodeficiency syndromes: a 5-year single-centre experience. J Paediatr Child Health. 2017;53(10):988–94.

  18. 18.

    Olaya-Vargas A, Coronel-Moran R, Rivera-Luna R, Bravo-Lindoro A, Bejar-Ramírez Y, Lormendez-Jacome D. Trasplante de células progenitoras hematopoyéticas en pediatría: Una alternativa de tratamiento en immunodeficiencias primarias. Rev Investig Clin. 2005;57(2):324–32.

    Google Scholar 

  19. 19.

    Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Obstet Gynecol Surv. 2011;66(7):398–9.

  20. 20.

    Hladun R, Badell I, González M, Martínez AM, Sánchez de Toledo J, Olivé MT, et al. Análisis de la supervivencia de los niños con inmunodeficiencias primarias que han recibido un trasplante de progenitores hematopoyéticos en España. An Pediatría [Internet]. 2015 Feb;82(2):62–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1695403314002203

  21. 21.

    Pai SY, Cowan MJ. Stem cell transplantation for primary immunodeficiency diseases: the North American experience. Curr Opin Allergy Clin Immunol. 2014;14(6):521–6.

    CAS  Article  Google Scholar 

  22. 22.

    Díaz de Heredia C, Ortega JJ, Díaz MA, Olivé T, Badell I, González-Vicent M, et al. Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies. Bone Marrow Transplant. 2008;41(7):627–33.

  23. 23.

    Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434–46.

  24. 24.

    Chiesa R, Veys P. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol. 2012;8(3):255–67.

    CAS  Article  Google Scholar 

  25. 25.

    Patiroglu T, Akar H, Unal E, Ozdemir A, Karakukcu M. Hematopoietic stem cell transplant for primary immunodeficiency diseases: a single-center experience. Exp Clin Transplant [Internet]. 2017;15(3):337–43 Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med14&NEWS=N&AN=27001505.

    Google Scholar 

  26. 26.

    Heimall J, Puck J, Buckley R, Fleisher TA, Gennery AR, Neven B, et al. Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency patients: a consensus statement from the second pediatric blood and marrow transplant consortium. Biol Blood Marrow Transplant [Internet]. 2017;23(3):379–87. Available from:. https://doi.org/10.1016/j.bbmt.2016.12.619.

  27. 27.

    Amayiri N, Al-Zaben A, Ghatasheh L, Frangoul H, Hussein AA, N A, et al. Hematopoietic stem cell transplantation for children with primary immunodeficiency diseases: single center experience in Jordan. Pediatr Transplant [Internet]. 2013;17(4):394–402. Available from:. https://doi.org/10.1111/petr.12081.

    CAS  Article  Google Scholar 

  28. 28.

    Uppuluri R, Sivasankaran M, Patel S, Swaminathan VV, Ramanan KM, Ravichandran N, et al. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: challenges and outcome from a tertiary care center in South India. J Clin Immunol [Internet]. 2019;39(2):182–7 Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=30778805.

  29. 29.

    Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119(12):2949–55.

Download references

Author information




All authors contributed to the study conception and design. Material preparation, critical revision, data collection, and analysis were performed by Manuela Olaya, Alexis Franco, Mauricio Chaparro, Natalia Builes Restrepo, Jose L Franco, Marcela Estupiñan, David Aristizabal, Andrés F Zea-Vera, Jaime Patiño, Harry Pachajoa, Paola Perez, and Diego Medina Valencia. The first draft of the manuscript, quality control, and statistical analysis of data for the work were performed by Mayra Estacio, Eliana Manzi, and Estefania Beltran and all authors commented on previous versions of the manuscript. All authors listed in the title page have contributed significantly to the work. All authors read and approved the final manuscript version to be submitted and agreed to be accountable for all aspects of the work and to ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Diego Medina-Valencia.

Ethics declarations

The Institutional Review Board Ethics Committee of each center approved the study protocol

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Olaya, M., Franco, A., Chaparro, M. et al. Hematopoietic Stem Cell Transplantation in Children with Inborn Errors of Immunity: a Multi-center Experience in Colombia. J Clin Immunol (2020). https://doi.org/10.1007/s10875-020-00856-w

Download citation


  • Hematopoietic stem cell transplantation
  • transplant recipients
  • primary immunodeficiency diseases
  • pediatrics
  • haploidentical transplantations
  • child